Table 1.
Demographic Characteristics of Study Participants
| Parameter | Full Cohort With Blood Samples (n = 48) | Subgroup With LN Samples (n = 8) | Subgroup With Rectal Samples (n = 20) |
|---|---|---|---|
| Age, median (IQR), y | 56.5 (50–62) | 57.5 (50–62) | 58.5 (51–63) |
| Sex, no. (%) | |||
| Male | 46 (96) | 8 | 20 |
| Female | 1 (2) | 0 | 0 |
| Transgendera | 1 (2) | 0 | 0 |
| Race, no. (%) | |||
| White | 32 (67) | 6 (75) | 13 (65) |
| African | 6 (13) | 1 (13) | 1 (5) |
| Hispanic | 4 (8) | 0 (0) | 2 (10) |
| Asian | 1 (2) | 0 (0) | 0 (0) |
| Pacific Islander | 1 (2) | 0 (0) | 1 (5) |
| Mixed | 4 (8) | 1 (13) | 3 (15) |
| Duration of ART, median (IQR), y | 8.5 (5.0–12.4) | 10.9 (4.7–13.1) | 10.5 (5.3–12.5) |
| Viral load, copies/mL | <40 | <40 | <40 |
| CD4+ T-cell count, median (IQR) | |||
| Nadir, cells/μL | 216 (133–387) | 134 (80–383) | 143 (89–387) |
| Current, cells/μL | 684 (530–862) | 549 (429–719) | 669 (496–833) |
| Current, % | 32 (25–41) | 25 (21–31) | 30 (23–36) |
| Current CD8+ T-cell count, median (IQR), cells/μL | 914 (639–1091) | 1069 (893–1399) | 986 (745–1138) |
| Integrated HIV DNA, median (IQR), copies/106 T cells | 338.8 (153.4–700.9) (n = 48) | 449.7 (217.1–1850) (n = 7) | 1263 (413.5–1942) (n = 19) |
| HIV CA-US RNA, median (IQR), copies/106 T cells | 22.5 (11.8–38.6) (n = 44) | 75.3 (13.9–155.8) (n = 7) | 69.4 (18.3–301.3) (n = 16) |
| Ratio of HIV CA-US RNA to integrated DNA, median (IQR) | 0.065 (0.037–0.122) (n = 43) | 0.086 (0.041–0.328) (n = 7) | 0.041 (0.029–0.201) (n = 13) |
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range.
aTransgender woman, with use of exogenous estrogens unknown.